2025
Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials.
Jaime-Casas S, Zugman M, Barragan-Carrillo R, Zang P, Ebrahimi H, Mercier B, Castro D, Yip W, Li X, Dizman N, Salgia N, Hsu J, Nguyen C, Chehrazi-Raffle A, Zengin Z, Meza L, Pal S, Tripathi A. Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials. Journal Of Clinical Oncology 2025, 43: 813-813. DOI: 10.1200/jco.2025.43.5_suppl.813.Peer-Reviewed Original ResearchAny-grade adverse eventsAdvanced urothelial carcinomaObjective-response rateAntibody-drug conjugatesCombination regimensClinical trialsCheckpoint inhibitorsSafety/tolerability profileCombination therapyPublished prospective clinical trialsProspective clinical trialPeer-reviewed clinical trialsSystematic review of clinical trialsReview of clinical trialsRandom-effects modelEnfortumab vedotinSacituzumab govitecanUrothelial carcinomaProspective trialsTreatment landscapeMaculopapular rashEfficacy outcomesRetrospective studyToxicity profileCase reportP-1574. Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial
Aronin S, Dunne M, Puttagunta S. P-1574. Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial. Open Forum Infectious Diseases 2025, 12: ofae631.1741. PMCID: PMC11776810, DOI: 10.1093/ofid/ofae631.1741.Peer-Reviewed Original ResearchPresence of asymptomatic bacteriuriaAsymptomatic bacteriuriaUncomplicated UTIClinical failureMMITT populationTOC visitClinical responseEfficacy endpointTreatment armsTreatment of uncomplicated UTIUncomplicated urinary tract infectionsPredictor of clinical failureTreatment of UTIUrinary tract infectionAdult womenAnalysis of womenCausative uropathogensDouble-dummyActive controlled trialUTI symptomsDouble-blindAsymptomatic patientsPrimary endpointTract infectionsEfficacy outcomesSafety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS
Allegretti J, Feuerstadt P, Knapple W, Orenstein R, Pinton P, Sheh A, Khanna S. Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflammatory Bowel Diseases 2025, izae291. PMID: 39862395, DOI: 10.1093/ibd/izae291.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsRecurrent Clostridioides difficile infectionInflammatory bowel diseaseClostridioides difficile infectionWeeks of administrationPrevention of recurrent CDISerious treatment-emergent adverse eventsSubgroup analysisSustained clinical response ratesBowel diseaseSustained clinical responseClinical response rateModerate gastrointestinal symptomsUS Food and Drug AdministrationTreatment success rateFood and Drug AdministrationClinical responseSingle-doseProspective trialsFecal microbiotaEfficacy outcomesDifficile infectionAdverse eventsGastrointestinal symptomsTreatment successEfficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients With Moyamoya Disease
Chen H, Colasurdo M, Khunte M, Malhotra A, Gandhi D. Efficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients With Moyamoya Disease. Neurology 2025, 104: e210243. PMID: 39772663, DOI: 10.1212/wnl.0000000000210243.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeTreated with IV thrombolysisIn-hospital mortalityMoyamoya disease patientsIV thrombolysisMoyamoya diseasePropensity score matchingIntracranial hemorrhageRisk factors of acute ischemic strokeSelf-careIschemic stroke patientsAcute ischemic stroke patientsStroke patientsTreating acute ischemic strokeNationwide Readmissions DatabaseRisk factorsRate of routine dischargeRoutine dischargeEfficacy outcomesAssociated with different ratesProspective studyBypass surgeryRetrospective analysisEstablished treatmentReadmissions Database
2024
Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour E. Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Frontiers In Oncology 2024, 14: 1455378. PMID: 39634261, PMCID: PMC11615674, DOI: 10.3389/fonc.2024.1455378.Peer-Reviewed Original ResearchMatching-adjusted indirect comparisonChronic-phase chronic myeloid leukemiaChronic myeloid leukemiaT315I mutationCP-CMLMyeloid leukemiaTyrosine kinase inhibitor therapyIndirect comparisonsResponse rateBaseline responsesSecond-generation TKIsT315I mutation statusKinase inhibitor therapyThird-line therapyMedical literature databasesInhibitor therapyMutation subgroupsMutation statusPatient-level dataEfficacy outcomesBaseline characteristicsMMR rateProportion Z testClinical trialsCumulative rateDeucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s423. DOI: 10.25251/skin.8.supp.423.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateParent trialAdverse cardiovascular eventsTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsCardiovascular eventsSafety signalsPatientsResponse rateIncidence ratePsoriasisEfficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
Zhang H, Lafayette R, Wang B, Ying L, Zhu Z, Stone A, Kristensen J, Barratt J. Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results. Kidney360 2024, 5: 1881-1892. PMID: 39724565, PMCID: PMC11687989, DOI: 10.34067/kid.0000000583.Peer-Reviewed Original ResearchEfficacy end pointImmunoglobulin A nephropathyEnd pointsImmune-mediated kidney diseasesGlobal study populationNo severe infectionsPreservation of eGFRIgAN pathophysiologyPrimary IgANDouble-blindEGFR reductionConsistent with global studiesEfficacy outcomesNo deathsAdverse eventsSevere infectionsChina cohortFollow-upPlaceboKidney diseaseSafety signalsBudesonide formulationIgANSupportive carePatientsAdjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
Adeoye O, Broderick J, Derdeyn C, Grotta J, Barsan W, Bentho O, Berry S, Concha M, Davis I, Demel S, Elm J, Gentile N, Graves T, Hoffman M, Huang J, Ingles J, Janis S, Jasne A, Khatri P, Levine S, Majjhoo A, Panagos P, Pancioli A, Pizzella S, Ranasinghe T, Sabagha N, Sivakumar S, Streib C, Vagal A, Wilson A, Wintermark M, Yoo A, Barreto A. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. New England Journal Of Medicine 2024, 391: 810-820. PMID: 39231343, PMCID: PMC11528349, DOI: 10.1056/nejmoa2314779.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsArginineCombined Modality TherapyDrug Therapy, CombinationEptifibatideFemaleFibrinolytic AgentsHumansIncidenceInfusions, IntravenousIntracranial HemorrhagesIschemic StrokeMaleMiddle AgedPeptidesPipecolic AcidsPlatelet Aggregation InhibitorsSingle-Blind MethodSulfonamidesThrombectomyThrombolytic TherapyTreatment OutcomeConceptsSymptomatic intracranial hemorrhageIntravenous argatrobanIntravenous thrombolysisAcute ischemic strokeIntracranial hemorrhageIschemic strokeIncidence of symptomatic intracranial hemorrhageSymptom onsetIschemic stroke treated with intravenous thrombolysisAcute ischemic stroke treated with intravenous thrombolysisStroke treated with intravenous thrombolysisAssociated with increased mortalityRankin Scale scoreInitiation of thrombolysisControlled clinical trialsTreatment of acute ischemic strokePlacebo groupEptifibatide groupEfficacy outcomesArgatroban groupStandard treatmentAdjunctive treatmentPlaceboClinical trialsArgatrobanA phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol
Palmisiano N, Lee J, Claxton D, Paietta E, Alkhateeb H, Park J, Podoltsev N, Atallah E, Schaar D, Dinner S, Webster J, Luger S, Litzow M. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol. EJHaem 2024, 5: 951-956. PMID: 39415930, PMCID: PMC11474352, DOI: 10.1002/jha2.991.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaMaximum tolerated doseT-cell acute lymphoblastic leukemiaLymphoblastic lymphomaLymphoblastic leukemiaTreatment-related adverse eventsDose level 3MRD-negative responseDose level 2Dose-limiting toxicityPhase I portionDose-escalation designPhase I/II trialPhase 1 trialPhase I objectivesPhase 2 portionAcute lymphoblastic leukemia subjectsEscalation designTolerated doseLiposomal vincristinePreclinical dataTherapeutic challengeEfficacy outcomesT cellsT-ALLDeucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s406. DOI: 10.25251/skin.8.supp.406.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsSafety signalsPatientsContinuous treatmentResponse rateIncidence rateParent trialPsoriasisAllosteric TYK2 inhibitorTenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial
Xiong Y, Wang L, Pan Y, Wang M, Schwamm L, Duan C, Campbell B, Li S, Hao M, Wu N, Cao Z, Wu S, Li Z, Wang Y. Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial. Stroke And Vascular Neurology 2024, 10: 112-119. PMID: 38858097, PMCID: PMC11877429, DOI: 10.1136/svn-2023-003048.Peer-Reviewed Original ResearchSymptomatic intracranial haemorrhageAcute ischaemic strokeModified Rankin ScaleElderly patientsPost hoc analysisAlteplase groupTenecteplase groupHoc analysisAlternative to alteplaseModified Rankin scale 0Ischaemic strokeRisk-benefit profileNon-inferiority clinical trialBenefit-risk profileEfficacy outcomesProportion of participantsReperfusion therapyIntracranial haemorrhageClinical trialsRankin ScaleSymptom onsetTenecteplaseAlteplaseIntravenous thrombolyticsSafety outcomesUnveiling consistency: A large-scale analysis of conference proceedings and subsequent publications in oncology clinical trials using large language models.
Lee K, Paek H, Huang L, Datta S, Annan A, Ofoegbu N, Higashi M, Hilton C, Rubinstein S, Cowan A, Kwok M, Warner J, Xu H, Wang X. Unveiling consistency: A large-scale analysis of conference proceedings and subsequent publications in oncology clinical trials using large language models. Journal Of Clinical Oncology 2024, 42: 7568-7568. DOI: 10.1200/jco.2024.42.16_suppl.7568.Peer-Reviewed Original ResearchAmerican Society of Clinical Oncology conferencesConference abstractsOncology clinical trialsStudies due to variationsEfficacy outcomesP-valueTwo-proportion z-testClinical trialsMinimal residual disease negativityLung cancer studiesPublished articlesTrial abstractsGood partial responseCohort sizeCytokine release syndromeOutcome valuesFollow-up timeOverall response rateTrial findingsClinical trial findingsTime pointsCancer studiesClinical decisionsDiverse cancer typesComplete responseImpact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
Petrylak D, Chia Y, Yu E, Powles T, Flaig T, Loriot Y, O'Donnell P, Heath E, Kojima T, Park S, Sonpavde G, Picus J, Matsubara N, Obara W, Chudasama V, Poondru S, Harrison M, Kim E, Brancato S, Rosenberg J. Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer. Journal Of Clinical Oncology 2024, 42: 4503-4503. DOI: 10.1200/jco.2024.42.16_suppl.4503.Peer-Reviewed Original ResearchMetastatic urothelial cancerEnfortumab vedotinDose modificationEV exposureUrothelial cancerPre-dose samplesAssociated with lower riskPopulation PK modelLikelihood of responseEV-201Median PFSOS benefitOS outcomesDose reductionExposure quartilesExposure-responsePK assessmentEfficacy outcomesSafety profilePeripheral neuropathySkin reactionsPK modelLow riskSafety outcomesDose responseTrastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
Oh D, Lugowska I, Stroyakovskiy D, Jung K, Dumas O, Penkov K, Dechaphunkul A, Oaknin A, Kim S, Starling N, Chewaskulyong B, Charonpongsuntorn C, Doroshow D, Hsiao S, Hung Y, Jung L, Kuptsova-Clarkson N, Michelini F, Puvvada S, Meric-Bernstam F. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). Journal Of Clinical Oncology 2024, 42: 4090-4090. DOI: 10.1200/jco.2024.42.16_suppl.4090.Peer-Reviewed Original ResearchBiliary tract cancerProgression-free survivalT-DXdPancreatic cancerHER2 expressionEfficacy outcomesDrug-related interstitial lung diseaseOpen-label phase 2 studyPC cohortDrug-related adverse eventsLate-line treatmentPrimary tumor locationPhase 2 studyGrade (GClinically meaningful benefitInterstitial lung diseaseHER2-expressing tumorsAdvanced/metastatic diseaseData cutoffIHC 3PD-L1Trastuzumab deruxtecanExploratory endpointsTumor locationPrimary endpointEfficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
Wysocki P, Jung K, Oh D, Doroshow D, Artamonova E, Mammatas L, SU P, Moiseyenko V, Penkov K, Stroyakovskiy D, Bartolome J, Siena S, Fielding A, Jung L, Michelini F, Puvvada S, Makker V. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. Journal Of Clinical Oncology 2024, 42: 4565-4565. DOI: 10.1200/jco.2024.42.16_suppl.4565.Peer-Reviewed Original ResearchDisease control rateProgression-free survivalDuration of responseT-DXdPretreated ptsHER2 expressionUrothelial cancerBladder cohortEfficacy outcomesSolid tumorsSafety of trastuzumab deruxtecanDrug-related adverse eventsPhase 2 studyClinically meaningful responseGrade (GHER2 expression levelsTrastuzumab deruxtecanAdvanced/metastatic diseaseData cutoffPD-L1Open-labelExploratory endpointsPrimary endpointSystemic treatmentSecondary endpointsA randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis
Ehst B, Strober B, Blauvelt A, Maslin D, Macaro D, Carpenter N, Bodmer M, McHale D. A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis. Frontiers In Medicine 2024, 11: 1292406. PMID: 38813388, PMCID: PMC11133679, DOI: 10.3389/fmed.2024.1292406.Peer-Reviewed Original ResearchPASI-50Double-blindMild to moderate plaque psoriasisMild to moderate psoriasisOff-treatment responseWeeks of follow-upChronic inflammatory skin diseaseParallel-group studySystemic anti-inflammatory responsePhase 2 trialInflammatory skin diseaseAnti-inflammatory responsePlaque psoriasisPlacebo-controlledPsoriasis AreaEfficacy outcomesImmunomodulatory approachesSafety profileAdverse eventsEvaluate safetyFollow-upTreatment periodTherapeutic benefitPsoriasisSkin diseasesDeucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Berger V, Vritzali E, Hoyt K, Colombo M, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s366. DOI: 10.25251/skin.8.supp.366.Peer-Reviewed Original ResearchModified nonresponder imputationPlaque psoriasisModerate to severe plaque psoriasisDiscontinuations due to AEsExposure-adjusted incidence ratesSevere plaque psoriasisParent trialAdverse cardiovascular eventsLong-term extensionTreatment of adultsSystemic therapyNonresponder imputationEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismDeucravacitinibCardiovascular eventsEfficacy resultsPatientsResponse rateIncidence ratePsoriasisAllosteric TYK2 inhibitorEfficacySafety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease
Hajós M, Boasso A, Hempel E, Shpokayte M, Konisky A, Seshagiri C, Fomenko V, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Kern R, Megerian J, Malchano Z. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Frontiers In Neurology 2024, 15: 1343588. PMID: 38515445, PMCID: PMC10957179, DOI: 10.3389/fneur.2024.1343588.Peer-Reviewed Original ResearchAssessment of adverse eventsMild to moderate ADGamma oscillationsModerate ADAmyloid-related imaging abnormalitiesAlzheimer's diseaseMild-to-moderate Alzheimer's diseaseSecondary clinical outcome measuresTherapy systemPrimary outcome measureHigher adherence ratesWhole-brain volumeClinical outcome measuresSecondary outcome measuresModerate Alzheimer's diseaseDisease-modifying effectsBaseline MMSE scoreStudy discontinuationExperimental AD modelsWell-toleratedEfficacy outcomesClinical benefitAdverse eventsDaily treatmentClinical criteriaEffect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial
dos Santos P, Messina N, de Oliveira R, da Silva P, Puga M, Dalcolmo M, dos Santos G, de Lacerda M, Jardim B, de Almeida e Val F, Curtis N, Andrews J, Croda J. Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial. The Lancet Infectious Diseases 2024, 24: 594-601. PMID: 38423021, PMCID: PMC11111441, DOI: 10.1016/s1473-3099(23)00818-6.Peer-Reviewed Original ResearchConceptsQuantiFERON-TB GoldPlacebo groupEffect of BCG vaccinationBCG vaccinationBCG groupBCG-DenmarkHealth-care workersNegative baseline resultsMonths of treatmentMycobacterium tuberculosis infectionAdult pulmonary tuberculosisQuantiFERON-TBMedian ageRandomised controlled trialsPulmonary tuberculosisNo significant differenceEfficacy outcomesTuberculosis infectionClinical trialsControlled trialsEffect of vaccinationTreatment drugsTuberculosis preventionSubstudySignificant differenceOutcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial
Li S, Wangqin R, Pan Y, Jin A, Li H, Schwamm L, Fisher M, Campbell B, Parsons M, Wang Z, Dai H, Li D, Li R, Wang J, Wang D, Wang Y, Zhao X, Li Z, Zheng H, Xiong Y, Meng X, Wang Y. Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial. Stroke And Vascular Neurology 2024, 9: svn-2023-002694. PMID: 38296586, PMCID: PMC11791627, DOI: 10.1136/svn-2023-002694.Peer-Reviewed Original ResearchOnset to treatment timeAcute ischaemic strokeEfficacy outcomesSubgroup analysisPost hoc subgroup analysisModified Rankin Scale scoreIschaemic strokeExcellent functional outcomeAcute ischaemic stroke patientsBenefit of intravenous alteplasePooled risk differenceRankin Scale scoreSymptomatic intracranial haemorrhageControlled clinical trialsStroke onset to treatment timePost hoc analysisNon-inferiority trialOpen-labelTenecteplase groupIntravenous tenecteplaseNon-inferior to alteplaseProportion of participantsReperfusion therapyIntracranial haemorrhageIntravenous alteplase
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply